# 2026-04918: FDA Guides Makers on Faster Weight-Loss Device Approvals

2026-04918, Medical Devices With Indications Associated With Weight Loss-Premarket Considerations; Guidance for Industry and Food and Drug Administration Staff; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-13, effective 2026-03-13; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04918
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04918
- Title: Medical Devices With Indications Associated With Weight Loss-Premarket Considerations; Guidance for Industry and Food and Drug Administration Staff; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 12429
- Published: 2026-03-13
- Effective: 2026-03-13
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Guides Makers on Faster Weight-Loss Device Approvals

## Summary

The FDA just released new guidance to help companies get their weight-loss medical devices approved faster and safer. This affects anyone making devices that claim to help with weight loss, with clear steps on testing and proving benefits before selling. The guidance is effective now, so expect smoother reviews and smarter investments in device development.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Medical Devices with Indications Associated with Weight Loss--Premarket Considerations." This guidance document provides recommendations regarding non-clinical testing and clinical study design for medical devices with indications for use associated with weight loss to support premarket submissions. The guidance also includes discussion on how FDA considers the benefit-risk analysis to support such indications.

## Effects PRIA read

- Final Guidance for Weight-Loss Devices: benefit, medium. On March 13, 2026, the FDA published a final guidance titled "Medical Devices with Indications Associated with Weight Loss--Premarket Considerations." The guidance gives recommendations on non-clinical testing and clinical study design to support premarket submissions for devices that claim weight…
- Specific Trial Design Clarifications Included: benefit, medium. The final guidance explicitly discusses use of sham controls, statistical analysis using modified intent-to-treat populations, and inclusion of patient-reported outcomes as part of benefit-risk evaluation. It also references FDA's Q-Submission Program as a way to request feedback on proposed clinic…
- Intended to Speed and Standardize Reviews: benefit, medium. FDA states the recommendations reflect current review practices and are "intended to promote consistency and facilitate efficient review" of premarket submissions for weight-loss devices. The guidance consolidates two prior draft guidances into one final document to ease use.
- No New Paperwork Collections Listed: benefit, low. The guidance states it contains no new collection of information under the Paperwork Reduction Act and refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0078, 0910-0844, 0910-0756, 0910-0485, 0910-0073, 0910-0130, and 0910-0119. Those existing…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04918 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/13/2026-04918/medical-devices-with-indications-associated-with-weight-loss-premarket-considerations-guidance-for)
- [2026-04918 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-13/pdf/2026-04918.pdf)

## Related
- [Previous: 2026-04917, Agency Information Collection Activities: Request for Comments for a New Inform…](https://policyrisk.com/federal-register/2026-04917)
- [Next: 2026-04920, Submission for OMB Review; Comment Request](https://policyrisk.com/federal-register/2026-04920)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04918 (as of 2026-06-08).
